1️⃣ EU puts a number on trial competitiveness EMA, HMA and the European Commission published the first 2026 progress readout against the EU’s 2030 clinical-trial targets: 19 extra multinational trials versus the historical average, and 40.5% of trials recruiting within 200 days.
💡 Why it matters Europe has moved from ambition to scoreboard. Sponsors now have a public benchmark for whether CTIS and FAST-EU are actually shortening time to patients.
☕ Coffee talk If the 2030 target is 66%, which countries are still making sponsors wait?
2️⃣ Regeneron buys into intracellular delivery Regeneron signed a Parabilis collaboration with $125 million near-term and up to about $2.2 billion in milestones to build antibody-Helicon conjugates across five initial targets.
💡 Why it matters Large pharma is still paying for modality expansion, but the risk is shifting to delivery, CMC and target selection rather than another plain ADC payload race.
☕ Coffee talk Who else with a peptide-delivery story now thinks it has a Regeneron comp?
3️⃣ Merck gets its first sac-TMT phase 3 win Merck said TroFuse-005 met overall-survival and progression-free-survival endpoints for sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer.
💡 Why it matters The Kelun-origin TROP2 ADC now has a pivotal oncology proof point, just months after Blackstone agreed to fund part of Merck’s 2026 sac-TMT development spend.
☕ Coffee talk Does this make sac-TMT a platform asset, or just a very expensive endometrial signal for now?